Puma Biotechnology (PBYI) Sell-Off on ASCO Abstract 'May be Overdone', Stifel Says
Tweet Send to a Friend
Stifel analyst Thomas Shrader weighed in on Puma Biotechnology (NYSE: PBYI) after the 20% sell-off in the stock following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
